Eloxx Pharmaceuticals Inc (OTCPK:ELOX)
$ 0.655 -0.085 (-11.49%) Market Cap: 2.06 Mil Enterprise Value: 3.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Eloxx Pharmaceuticals, Inc. - Special Call Transcript

Jan 14, 2020 / 07:30PM GMT
Release Date Price: $211.2 (-30.34%)
Asher Hodes
Covington & Burling LLP - Associate

Welcome, everyone. I'm Asher Hodes from Covington & Burling. The next presenting company is Eloxx Pharmaceuticals from Waltham, Massachusetts. Eloxx is focused on orphan and rare diseases, platform technology, and pulmonary, renal and ophthalmic indications.

Presenting for Eloxx Pharmaceuticals is their Chairman and CEO, Robert Ward. There will be a breakout afterwards in public breakout room #2.

Robert E. Ward
Eloxx Pharmaceuticals, Inc. - Chairman & CEO

Thank you very much for joining me today for our first presentation to kick off 2020. During the course of my presentation today on Eloxx Pharmaceuticals, I'll be making forward-looking statements, and I'd ask that you refer to our most recent 10-K and other SEC filings.

2019 was a very exciting year with the completion of our first cohort in cystinosis. And today, I'll be sharing with you the top line results from that program as well as an update on our Phase II trial in cystic fibrosis and the promising activities that we see

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot